Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001181431-14-032981
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-01 16:36:46
Reporting Period:
2014-09-29
Filing Date:
2014-10-01
Accepted Time:
2014-10-01 16:36:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157602 Vitae Pharmaceuticals Inc VTAE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1005561 J Peter Barris 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
1132326 P L 10 Associates Enterprise New 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
1219855 James M Barrett 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
1236049 P L 10 Partners Nea 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
1237289 D Scott Sandell 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-09-29 260,340 $0.00 260,340 No 4 C Direct
Common Stock Acquisiton 2014-09-29 1,479,058 $0.00 1,739,398 No 4 C Direct
Common Stock Acquisiton 2014-09-29 58,692 $0.00 1,798,090 No 4 C Direct
Common Stock Acquisiton 2014-09-29 813,474 $8.00 2,611,564 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Direct
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A-2 Preferred Stock Disposition 2014-09-29 172,825 $0.00 260,340 $0.00
Common Stock Series B Preferred Stock Disposition 2014-09-29 1,479,058 $0.00 1,479,058 $0.00
Common Stock Series C Preferred Stock Disposition 2014-09-29 58,692 $0.00 58,692 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Each outstanding share of Series A-2 Preferred Stock automatically converted on a 1:1.50638118 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.
  2. The shares are directly held by New Enterprise Associates 10, Limited Partnership ("NEA 10") and indirectly held by NEA Partners 10, Limited Partnership ("NEA Partners 10"), the sole general partner of NEA 10, and the individual general partners of NEA Partners 10 (NEA Partners 10 and its individual general partners together, the "Indirect Reporting Persons"). The individual general partners of NEA Partners 10 are Peter J. Barris, M. James Barrett and Scott D. Sandell. Each Indirect Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which such Indirect Reporting Person has no pecuniary interest.
  3. Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the Issuer's initial public offering, for no additional consideration.